Martin Pal

Dr Martin Pal

Medical Scientist

Dentistry and Medical Sciences

Biography

Dr Martin Pal is an expert in genome editing and CRISPR-technology and has extensive research experience across multiple disease backgrounds (metabolism, exercise, cancers including liver, breast, blood).

Dr Pal received his PhD in Genetics from the University of Cologne, Germany, and before joining Charles Sturt in 2021, Dr Pal performed postdoctoral research at four of Australia’s preeminent medical research institutes (WEHI, JCSMR, Garvan, Baker IDI.

Dr Pal’s research focusses on developing novel genetic models using CRISPR-technology (Pillar 2 of THRIIVE); discovery driven-work with CRISPR-technology for novel drug targets (Pillar 2 of THRIIVE); and developing novel detection methods for domestic zoonotic pathogens using CRISPR Diagnostics (ECR Grant, 2022) (Pillar 3 of THRIIVE). In addition, Dr Pal played a pivotal role in the generation of the recently launched online learning course “CRISPR 101", which utilises innovative online learning tools to foster community engagement (Pillar 4 of THRIIVE)

In collaboration with Prof Jade Forwood he is investigating mechanisms of nuclear import for both cancer-driving and tumour-suppressing genes with the aim of finding novel therapeutic avenues

Research
  • developing novel genetic models using CRISPR-technology
  • discovery driven-work with CRISPR-technology for novel drug targets
  • developing novel detection methods for domestic zoonotic pathogens using CRISPR Diagnostics
Publications
Full publications list on CRO

Recent publications

  • Yew, M. J., Heywood, S. E., Ng, J., West, O. M., Pal, M., Kueh, A., Lancaster, G. I., Myers, S., Yang, C., Liu, Y., Reibe, S., Mellett, N. A., Meikle, P. J., Febbraio, M. A., Greening, D. W., Drew, B. G., & Henstridge, D. C. (2024). ACAD10 is not required for metformin's metabolic actions or for maintenance of whole-body metabolism in C57BL/6J mice. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics. Advance online publication. https://doi.org/10.1111/dom.15484
  • Potts, M. A., Mizutani, S., Garnham, A. L., Li Wai Suen, C. S. N., Kueh, A. J., Tai, L., Pal, M., Strasser, A., & Herold, M. J. (2023). Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis. Cell Death and Differentiation. https://doi.org/10.1038/s41418-023-01145-w
  • Deng, Y., Diepstraten, S. T., Potts, M. A., Giner, G., Trezise, S., Ng, A. P., Healey, G., Kane, S. R., Cooray, A., Behrens, K., Heidersbach, A., Kueh, A. J., Pal, M., Wilcox, S., Tai, L., Alexander, W. S., Visvader, J. E., Nutt, S. L., Strasser, A., ... Herold, M. J. (2022). Author Correction: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance (Nature Communications, (2022), 13, 1, (4739), 10.1038/s41467-022-32485-9). Nature Communications, 13(1), 1-1. [5007]. https://doi.org/10.1038/s41467-022-32817-9
  • Pal, M., Cranna, N., Herold, M. J., & O’Brien, K. B. (2022). Case Study: CRISPR 101 – a novel online learning course harnessing innovative ways to teach a complex biomolecular technology. Essays in Biochemistry, 66(1), 11-18. https://doi.org/10.1042/EBC20220024
  • Deng, Y., Diepstraten, S. T., Potts, M. A., Giner, G., Trezise, S., Ng, A. P., Healey, G., Kane, S. R., Cooray, A., Behrens, K., Heidersbach, A., Kueh, A. J., Pal, M., Wilcox, S., Tai, L., Alexander, W. S., Visvader, J. E., Nutt, S. L., Strasser, A., ... Herold, M. J. (2022). Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance. Nature Communications, 13(1), 1-17. [4739]. https://doi.org/10.1038/s41467-022-32485-9